CONSTANT LEVERAGE LONG - NOVO-NORDISK B | Real-time Euronext Paris 08:44:15 04/06/2024 pm IST | ||
| 4.52 EUR | +8.52% |
|
| Current month | +10.24% | ||
| 1 month | +109.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 4.52 | +8.52% |
| 03/24/03 | 4.165 | +1.59% |
| 31/24/31 | 4.1 | +5.26% |
| 30/24/30 | 3.895 | +5.13% |
| 29/24/29 | 3.705 | -5.12% |
Real-time Euronext Paris
Last update June 04, 2024 at 08:44 pm IST
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| 5FLMB | |
| ISIN | NLBNPNL2IDX9 |
| Date issued | 20/09/2023 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.845 € |
|---|---|
| Lowest since issue | 0.496 € |
| Spread | 0.08 € |
| Spread % | 1.87% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
936.2
DKK
Average target price
917.3
DKK
Spread / Average Target
-2.02%
- Stock Market
- Certificates
- 5FLMB Certificat
